Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bacterial Infections and Mycoses

  Free Subscription

Articles published in
Lancet
    March 2024
  1. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    >> Share

  2. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    >> Share

  3. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    >> Share

  4. BHARGAVA A, Bhargava M, Pai M
    Tuberculosis: a biosocial problem that requires biosocial solutions.
    Lancet. 2024 Mar 20:S0140-6736(24)00489-6. doi: 10.1016/S0140-6736(24)00489.
    >> Share

  5. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    >> Share

  6. SUBBARAMAN R, Fielding K
    Putting technology to the test in tuberculosis care.
    Lancet. 2024;403:878-879.
    >> Share

    February 2024
  7. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    >> Share

  8. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    >> Share

  9. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    >> Share

  10. PETERS RPH, Klausner JD, Mazzola L, Mdingi MM, et al
    Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
    Lancet. 2024;403:657-664.
    >> Share

  11. PAI NP, Dillon JR
    A lateral flow assay for Neisseria gonorrhoeae: a step forward for an inexpensive biomarker-based diagnosis of N gonorrhoeae at the point of care?
    Lancet. 2024;403:594-595.
    >> Share

    January 2024
  12. WEI X, Hicks JP, Zhang Z, Haldane V, et al
    Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
    Lancet. 2024 Jan 31:S0140-6736(23)02270-5. doi: 10.1016/S0140-6736(23)02270.
    >> Share

  13. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    >> Share

  14. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.
    >> Share

  15. CHICOINE N, Greenberg S
    Severe colonic distention and malnutrition in a 6-week-old infant: a case of Hirschsprung-associated enterocolitis.
    Lancet. 2024;403:282.
    >> Share

    November 2023
  16. SAMARASEKERA U
    Anurag and Madhavi Bhargava: enhancing TB prevention and care.
    Lancet. 2023;402:1740.
    >> Share

  17. WRENN K, Blomquist PB, Inzoungou-Massanga C, Olufon O, et al
    Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile.
    Lancet. 2023;402 Suppl 1:S93.
    >> Share

    October 2023
  18. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.
    >> Share

  19. BURKI T
    J&J patent decision to enable generic tuberculosis treatment.
    Lancet. 2023;402:1313.
    >> Share

    September 2023
  20. THE LANCET
    Tuberculosis: a different way of doing things.
    Lancet. 2023;402:937.
    >> Share

  21. REID M, Agbassi YJP, Arinaminpathy N, Bercasio A, et al
    Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01379-X. doi: 10.1016/S0140-6736(23)01379.
    >> Share

  22. BEKO B, Furin J
    Beyond individual inclusion, investment in affected communities is needed to end tuberculosis.
    Lancet. 2023 Sep 13:S0140-6736(23)01892-5. doi: 10.1016/S0140-6736(23)01892.
    >> Share

    August 2023
  23. NELSON R
    Syphilis rates soar in the USA amid penicillin shortage.
    Lancet. 2023;402:515.
    >> Share

  24. BHARGAVA A, Bhargava M, Meher A, Benedetti A, et al
    Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
    Lancet. 2023 Aug 8:S0140-6736(23)01231-X. doi: 10.1016/S0140-6736(23)01231.
    >> Share

  25. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    >> Share

    July 2023
  26. PEELING RW, Mabey D, Chen XS, Garcia PJ, et al
    Syphilis.
    Lancet. 2023;402:336-346.
    >> Share

    May 2023
  27. RICHARD M, Amiens P, Arregle F, Courand PY, et al
    Myocardial calcification: a rare consequence of streptococcal toxic shock.
    Lancet. 2023;401:1691.
    >> Share

    April 2023
  28. HAWKEY C
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved - Author's reply.
    Lancet. 2023;401:1266.
    >> Share

  29. GATTA L, Zullo A, Vaira D
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved.
    Lancet. 2023;401:1265-1266.
    >> Share

  30. REID M, Yamey G, Goosby E, Jamison D, et al
    Seizing opportunities to end TB: a call for ambition and optimism on World TB Day.
    Lancet. 2023;401:1153.
    >> Share

    March 2023
  31. KIRBY T
    Ruvandhi Nathavitharana: advancing TB diagnostics and advocacy.
    Lancet. 2023;401:990.
    >> Share

  32. KASAEVA T, Dias HM, Pai M
    Fast-tracking progress to End TB: high-level opportunities for investment and action.
    Lancet. 2023;401:975-978.
    >> Share

  33. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    >> Share

  34. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.
    >> Share

  35. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    >> Share

  36. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    >> Share

    February 2023
  37. BURKI T
    "Things have gone seriously wrong": global cholera surges.
    Lancet. 2023;401:633-634.
    >> Share

  38. AZIMINIA N, Soman B, Samoes J, Randhawa R, et al
    A diagnostic conundrum of a "ring of fire": a case of tuberculous perimyocarditis.
    Lancet. 2023;401:470-471.
    >> Share

    January 2023
  39. THOMPSON GR 3RD, Soriano A, Cornely OA, Kullberg BJ, et al
    Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
    Lancet. 2023;401:49-59.
    >> Share

    December 2022
  40. DANIELS JP
    Cholera surges in Haiti.
    Lancet. 2022;400:1913.
    >> Share

    November 2022
  41. GUINEA J
    Rezafungin and invasive candida infections: a new game changing antifungal?
    Lancet. 2022 Nov 25:S0140-6736(22)02371-6. doi: 10.1016/S0140-6736(22)02371.
    >> Share


  42. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022 Nov 18:S0140-6736(22)02185-7. doi: 10.1016/S0140-6736(22)02185.
    >> Share

  43. GOODALL RL, Meredith SK, Nunn AJ, Bayissa A, et al
    Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02078.
    >> Share

  44. DHEDA K, Lange C
    A revolution in the management of multidrug-resistant tuberculosis.
    Lancet. 2022 Nov 7. pii: S0140-6736(22)02161.
    >> Share

  45. HAWKEY C, Avery A, Coupland CAC, Crooks C, et al
    Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1597-1606.
    >> Share

  46. LANAS A, Santilli F
    Aspirin and Helicobacter pylori interaction.
    Lancet. 2022;400:1560-1561.
    >> Share

  47. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    >> Share

  48. JACKSON S, Kabir Z, Comiskey C
    Divergence in pace of decline in tuberculosis rates among migrants versus non-migrants in Ireland from 2011 to 2020.
    Lancet. 2022;400 Suppl 1:S52.
    >> Share

    October 2022
  49. WIECH T, Reinhard L, Wulf S, Giuffrida AE, et al
    Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy.
    Lancet. 2022 Oct 31. pii: S0140-6736(22)02039.
    >> Share

  50. MOK J, Lee M, Kim DK, Kim JS, et al
    9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial i
    Lancet. 2022;400:1522-1530.
    >> Share

  51. REUTER A, Furin J
    Celebrating choice in the care of people living with drug-resistant tuberculosis.
    Lancet. 2022;400:1489-1491.
    >> Share

    September 2022
  52. DEVI S
    War driving cholera in Syria.
    Lancet. 2022;400:986.
    >> Share

    August 2022
  53. MARKS GB, Horsburgh CR Jr, Fox GJ, Nguyen TA, et al
    Epidemiological approach to ending tuberculosis in high-burden countries.
    Lancet. 2022 Aug 4. pii: S0140-6736(22)01433.
    >> Share

    May 2022
  54. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    >> Share

    April 2022
  55. PIETER Y, Grijsen ML
    Picturing health: the burden of leprosy in eastern Indonesia.
    Lancet. 2022;399:1588-1599.
    >> Share

  56. KANUNGO S, Azman AS, Ramamurthy T, Deen J, et al
    Cholera.
    Lancet. 2022;399:1429-1440.
    >> Share

    March 2022
  57. DHEDA K, Pinto L, Mutsvangwa J, Leung CC, et al
    Accelerate investment and action to find the missing patients with tuberculosis.
    Lancet. 2022 Mar 22. pii: S0140-6736(22)00535.
    >> Share

  58. YAKOVENKO V, Brauner R, Votinov E, Goldfarb Y, et al
    Infective endocarditis and thromboses due to antiphospholipid syndrome following acute Q fever.
    Lancet. 2022;399:1154.
    >> Share

  59. WATTS G
    Alberto Garcia-Basteiro: seeking better TB control in Mozambique.
    Lancet. 2022;399:1109.
    >> Share

    February 2022
  60. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    >> Share

  61. HEINING D, Plant AJ
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis.
    Lancet. 2022;399:717-718.
    >> Share

  62. VAN DE BEEK D, Brouwer MC, Koedel U, Wall EC, et al
    Steroid use in non-pneumococcal and non-Haemophilus bacterial meningitis - Authors' reply.
    Lancet. 2022;399:718.
    >> Share

  63. BEYRER C
    Archbishop Desmond Tutu and the universality of health and human rights.
    Lancet. 2022;399:503-504.
    >> Share

    January 2022
  64. VIGNESHWARAN J, Kumar MS, Raghavan V, Sundari S, et al
    Seizures and sideroblastic anaemia in a patient with multidrug-resistant tuberculosis.
    Lancet. 2022;399:393.
    >> Share


  65. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
    Lancet. 2022 Jan 18. pii: S0140-6736(21)02724.
    >> Share

  66. LAXMINARAYAN R
    The overlooked pandemic of antimicrobial resistance.
    Lancet. 2022 Jan 18. pii: S0140-6736(22)00087.
    >> Share

  67. MCCALL C
    Disrupted care in Papua New Guinea: the harms of COVID-19.
    Lancet. 2022;399:226-227.
    >> Share

    December 2021
  68. HOSSEINPOOR AR, Bergen N, Kirkby K, Schlotheuber A, et al
    Monitoring inequalities is a key part of the efforts to end AIDS, tuberculosis, and malaria.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)02756.
    >> Share

    November 2021
  69. LANE R
    Pascale Ondoa: strengthening laboratory medicine in Africa.
    Lancet. 2021;398:1955.
    >> Share

    October 2021
  70. BUTLER-LAPORTE G, Halme A, Simard C
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1485.
    >> Share

  71. DINH A
    Antibiotic treatment duration for bacteraemic pneumonia - Author's reply.
    Lancet. 2021;398:1485-1486.
    >> Share

  72. COUSSEMENT J, Dauby N
    Antibiotic treatment duration for bacteraemic pneumonia.
    Lancet. 2021;398:1484-1485.
    >> Share

  73. HEGDE A, Littlechild P, Taylor W
    Lumbar sediment sign seen in an unusual presentation of meningitis.
    Lancet. 2021;398:1436.
    >> Share

    September 2021
  74. LOW N, Hocking JS, van Bergen J
    The changing landscape of chlamydia control strategies.
    Lancet. 2021 Sep 22. pii: S0140-6736(21)02002.
    >> Share

  75. LANE R
    Gagandeep Kang: helping to shape a healthier India.
    Lancet. 2021;398:947.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016